GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inoviq Ltd (ASX:IIQ) » Definitions » Growth Rank

Inoviq (ASX:IIQ) Growth Rank : 0 (As of Jun. 04, 2024)


View and export this data going back to 1991. Start your Free Trial

What is Inoviq Growth Rank?

Inoviq has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Inoviq Growth Rank Related Terms

Thank you for viewing the detailed overview of Inoviq's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Inoviq (ASX:IIQ) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inoviq Ltd (ASX:IIQ) » Definitions » Growth Rank
Comparable Companies
ASX:CTE ASX:BDX ASX:LDX ASX:RHY ASX:GTG ASX:MAP ASX:IBX ASX:GSS TMO DHR A IDXX IQV XSWX:LONN MTD ICLR WAT ILMN LH SHSE:603259
Traded in Other Exchanges
N/A
Address
23 Normanby Road, Notting Hill, Melbourne, VIC, AUS, 3168
Website
https://www.bard1.com
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers.

Inoviq (ASX:IIQ) Headlines

No Headlines